Zobrazeno 1 - 10
of 500
pro vyhledávání: '"Kakkar, Ak"'
Autor:
Fox, KAA, Virdone, S, Bassand, J-P, Camm, AJ, Goto, S, Goldhaber, SZ, Haas, S, Kayani, G, Koretsune, Y, Misselwitz, F, Oh, S, Piccini, JP, Parkhomenko, A, Sawhney, JPS, Stepinska, J, Turpie, AGG, Verheugt, FWA, Kakkar, AK, GARFIELD-AF investigators
OBJECTIVE: In patients with newly diagnosed atrial fibrillation (AF), do baseline risk factors and stroke prevention strategies account for the geographically diverse outcomes. DESIGN: Global Anticoagulant Registry in the FIELD-Atrial Fibrillation is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::56f81169a3f834b48e89399d8144e73e
https://openaccess.sgul.ac.uk/id/eprint/114053/1/e049933.full.pdf
https://openaccess.sgul.ac.uk/id/eprint/114053/1/e049933.full.pdf
Autor:
Gibbs, H, Freedman, B, Rosenqvist, M, Virdone, S, Mahmeed, WA, Ambrosio, G, Camm, AJ, Jacobson, B, Jerjes-Sanchez, C, Kayani, G, Oto, A, Panchenko, E, Ragy, H, Kakkar, AK, GARFIELD-AF Investigators
BACKGROUND: Asymptomatic atrial fibrillation is often detected incidentally. Prognosis and optimal therapy for asymptomatic compared with symptomatic atrial fibrillation is uncertain. This study compares clinical characteristics, treatment, and 2-yea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::280bc9fd9d9a80eff5acbdc290ce44ca
https://openaccess.sgul.ac.uk/id/eprint/113018/6/1-s2.0-S0002934321000966-main.pdf
https://openaccess.sgul.ac.uk/id/eprint/113018/6/1-s2.0-S0002934321000966-main.pdf
Autor:
Fox, KAA, Velentgas, P, Camm, AJ, Bassand, J-P, Fitzmaurice, DA, Gersh, BJ, Goldhaber, SZ, Goto, S, Haas, S, Misselwitz, F, Pieper, KS, Turpie, AGG, Verheugt, FWA, Dabrowski, E, Luo, K, Gibbs, L, Kakkar, AK, GARFIELD-AF Investigators
Importance: Patients with nonvalvular atrial fibrillation at risk of stroke should receive oral anticoagulants (OAC). However, approximately 1 in 8 patients in the Global Anticoagulant Registry in the Field (GARFIELD-AF) registry are treated with ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::cd291dfb47b2bfedb3d7688734b6f74e
https://openaccess.sgul.ac.uk/id/eprint/111723/1/fox_2020_oi_200012.pdf
https://openaccess.sgul.ac.uk/id/eprint/111723/1/fox_2020_oi_200012.pdf
Autor:
Verheugt, FW, Ambrosio, G, Atar, D, Bassand, J-P, Camm, AJ, Costabel, JP, Fitzmaurice, DA, Illingworth, L, Goldhaber, SZ, Goto, S, Haas, S, Jansky, P, Kayani, G, Stepinska, J, Turpie, AG, van Eickels, M, Kakkar, AK, GARFIELD-AF Investigators
BACKGROUND: Many patients with atrial fibrillation have concomitant coronary artery disease with or without acute coronary syndromes and are in the need of additional antithrombotic therapy. There are few data on the long-term clinical outcome of atr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::b177fae28897458e5c3c74c236024e75
https://openaccess.sgul.ac.uk/id/eprint/111045/1/1-s2.0-S0002934319305431-main.pdf
https://openaccess.sgul.ac.uk/id/eprint/111045/1/1-s2.0-S0002934319305431-main.pdf
Autor:
Beyer-Westendorf, J, Camm, AJ, Fox, KAA, Le Heuzey, J-Y, Haas, S, Turpie, AGG, Virdone, S, Kakkar, AK, Investigators, RIVERR
Background\ud Real-world data on non-vitamin K oral anticoagulants (NOACs) are essential in determining whether evidence from randomised controlled clinical trials translate into meaningful clinical benefits for patients in everyday practice. RIVER (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::6c5dc0bf679203b02db90909419fdf25
https://openaccess.sgul.ac.uk/id/eprint/110862/1/document.pdf
https://openaccess.sgul.ac.uk/id/eprint/110862/1/document.pdf
There has been a longstanding problem of suboptimal use of anticoagulation in patients with atrial fibrillation (AF), however there is limited evidence relating to the period following the commencement of non-vitamin K antagonist oral anticoagulants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1064::b649e3692eaab4c839590b6bddcd4b16
https://ora.ox.ac.uk/objects/uuid:919ac0da-846f-4a3a-a3c6-5f11b7958534
https://ora.ox.ac.uk/objects/uuid:919ac0da-846f-4a3a-a3c6-5f11b7958534
Autor:
Raskob, GE, van Es, N, Verhamme, P, Carrier, M, Di Nisio, M, Garcia, D, Grosso, MA, Kakkar, AK, Kovacs, MJ, Mercuri, MF, Meyer, G, Segers, A, Shi, M, Wang, TF, Yeo, E, Zhang, G, Zwicker, JI, Weitz, JI, Büller, HR, Beyer-Westendorf, J, Boda, Z, Chlumsky, Y, Gibbs, H, Kamphuizen, PW, Monreal, M, Ockleford, P, Pabinger-Fasching, I, Sinnaeve, P, Beenen, L, Gerdes, V, Laleman, W, Larrey, D, van Mechelen, R, Roos, Y, Scheerder, M, Slagboom, T, Thijs, V, Eikelboom, JW, Crowther, M, Roberts, RS, Vanassche, T, Vandenbriele, C, Debaveye, B, Dani, V, Schwocho, L, Duggal, A, Baker, R, Carroll, P, Chan, N, Coughlin, P, Crispin, P, Gallus, A, Hugman, A, Tran, H, Brodmann, M, Mathies, R, Rossmann, D, Deeren, D, Hainaut, P, Jochmans, K, Vercauter, P, Wautrecht, JC, Champion, P, Gross, P, Lee, A, Shivakumar, S, Tagalakis, V, Zed, E, Kovarova, K, Lastuvka, J, Matoska, P, Prosecky, R, Achkar, A, Aquilanti, S, Chatellain, P, Cony-Makhoul, P, Del Piano, F, Elias, A, Falvo, N, Ferrari, E, Mahé, I, Merle, P, Mismetti, P, Muron, T, Pernod, G, Quere, I, Schmidt, J, Stephan, D, Espinola-Klein, C, Horacek, T, Kröning, R, Oettler, W, Schellong, S, Schön, N, Zwemmrich, C, Farkas, K, Gurzo, M, Nyirati, G, Pecsvarady, Z, Riba, M, Becattini, C, Cattaneo, M, Falanga, A, Ghirarduzzi, A, Imberti, D, Lodigiani, C, Parisi, R, Porreca, E, Squizzato, A, Tassoni, MI, Villalta, S, Visonà, A, Beeker, A, Boersma, W, Brouwer, R, Dees, A, Huisman, M, Kuijer, P, Mairuhu, R, Meijer, K, Middeldorp, S, Otten, HM, van Marwijk-Kooy, M, van Wissen, S, Westerweel, P, Harper, P, Merriman, E, Ockelford, P, Royle, G, Smith, M, Cereto Castro, F, de Oña Navarrete, R, Font Puig, C, Gallardo Díaz, E, Garcia-Bragado Dalmau, F, Ruiz Artacho, P, Santamaria, A, Baumann Kreuziger, L, De Sancho, M, Gaddh, M, Metjian, A, Rojas Hernandez, CM, Shah, V, Smith, W, Wun, T, Xiang, Z
Publikováno v:
New England journal of medicine, 378(7), 615-624. Massachussetts Medical Society
BACKGROUND Low-molecular-weight heparin is the standard treatment for cancer-associated venous thromboembolism. The role of treatment with direct oral anticoagulant agents is unclear. METHODS In this open-label, noninferiority trial, we randomly assi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f4a26cb2b7095a4b25056f7b4051a98
http://hdl.handle.net/10281/261195
http://hdl.handle.net/10281/261195
Autor:
Fox, KAA, Accetta, G, Pieper, KS, Bassand, J-P, Camm, AJ, Fitzmaurice, DA, Kayani, G, Kakkar, AK, GARFIELD-AF Investigators
Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::1e847b7b3d695bc51e2d51bfd083ce8a
https://openaccess.sgul.ac.uk/id/eprint/109177/1/document.pdf
https://openaccess.sgul.ac.uk/id/eprint/109177/1/document.pdf